Roivant Sciences Ltd (NAS:ROIVW)
$ 2.75 -0.11 (-3.85%) Market Cap: - Enterprise Value: - PE Ratio: 2.09 PB Ratio: 1.58 GF Score: 60/100

Roivant Sciences Ltd at UBS Global Healthcare Conference Transcript

May 23, 2022 / 01:15PM GMT
Operator

Good morning, everyone, and thank you so much for coming to the 2022 UBS Global Healthcare Conference. My name is Sylvie Chen, and I'm very happy to be your host for this session.

Our next presenter will be Matthew Gline, Chief Executive Officer from Roivant Sciences. A Q&A session will follow immediately after the presentation. (Operator Instructions) We now turn it over to Matt. Thank you.

Matthew Gline
Roivant Sciences Ltd. - CEO & Director

Thank you very much, and thank you for having me. I'm thrilled to be here. It's my -- certainly, first New York-based in-person conference in about 2 years. So if I'm a little bit rusty, I apologize. I'm used to doing this from my desk. Sorry, there's various disclaimers here that I think we've mostly run through.

Okay. You're good? Great. There we go. [Alex], that one looks familiar. I have my own disclaimer slide. I'll be making forward-looking statements in the course of today's presentation, and you can consult these disclaimers for more information.

Great. Well, again, thanks,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot